MedPath

Physiological Versus Right Ventricular Outcome Trial Evaluated for Bradycardia Treatment Upgrades

Not Applicable
Recruiting
Conditions
Pacing-Induced Cardiomyopathy
Heart Failure
Interventions
Device: Continued RV Pacing (Right Ventricular Pacing)
Device: Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)
Registration Number
NCT06052475
Lead Sponsor
Imperial College London
Brief Summary

Guidelines for patients having first-time implants advocate that even when heart function is only mildly impaired, modern pacing approaches should be utilised to avoid the potentially damaging effects of RV pacing to preventing symptoms from pacing induced or worsened cardiomyopathy.

However, once a traditional (RV) pacemaker is implanted, development of impaired heart function does not prompt a device upgrade. Even at the end of battery life, physicians simply replace it like-for-like.

This trial tests whether such patients have better symptoms and quality of life if changed to a modern physiological pacing strategy from the traditional RV pacing approach.

In this crossover trial, participants will be upgraded to a physiological pacing strategy.

After their procedure, they will have a one-month run-in period to recover from the procedure (their pacemaker will be programmed to continued RV pacing).

They will be have 2 one-month blinded time periods, randomised to physiological pacing or right ventricular pacing alternately. They will subsequently undergo two six-month blinded randomised time periods.

Patients will document symptoms monthly on a mobile phone application or computer. At the end of each time period, they will have measurements of heart function, a walking test and quality-of-life questionnaires including the SF-36 questionnaire.

The investigators hypothesise that upgrading to physiological pacing strategies will improve patients' quality of life.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
155
Inclusion Criteria

Not provided

Exclusion Criteria
  • Those unable to provide informed consent
  • Patients under age 18
  • Pregnant women

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Right Ventricular PacingContinued RV Pacing (Right Ventricular Pacing)Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice)
Physiological Pacing (Conduction System Pacing or Biventricular Pacing)Physiological Pacing Upgrade (Conduction System Pacing or Biventricular Pacing)The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
Primary Outcome Measures
NameTimeMethod
SF-36 (Short Form 36 Health Survey Questionnaire) Physical Component SummaryFrom date of baseline, until end of trial follow-up at fourteen months post-baseline
Secondary Outcome Measures
NameTimeMethod
BNP (B-type natriuretic peptide)From date of baseline, until end of trial follow-up at fourteen months post baseline visit

B-type natriuretic peptide blood test

Minnesota Living with Heart Failure QuestionnaireFrom date of baseline, until end of trial follow-up at fourteen months
Six-minute walk testFrom date of baseline, until end of trial follow-up at fourteen months

Measured in distance in metres

Atrial fibrillationFrom date of baseline, until end of trial follow-up at fourteen months

(atrial fibrillation percentage burden as measured by pacemaker device - %)

Left ventricular ejection fractionFrom date of baseline, until end of trial follow-up at fourteen months

(% ejection fraction)

Left ventricular end systolic volumeFrom date of baseline, until end of trial follow-up at fourteen months

(millilitres)

Safety endpointsFrom device implant date, assessed up to 15 months at the end of the trial (including a one-month run-in period post-procedure prior to the first baseline visit)

Device infections (requiring device extraction), pacing thresholds, need for lead revision or reimplantation, generator change, haematoma and pneumothorax

SF-36 (Short Form 36 Health Survey Questionnaire) Overall ScoreFrom date of baseline, until end of trial follow-up at fourteen months post baseline visit
Patient preference based on blinded symptomatic preferenceAt 2 months following baseline and 14 months following baseline visit
EQ-5D QuestionnaireFrom date of baseline, until end of trial follow-up at fourteen months post-baseline visit

EQ-5D is the name of the instrument and is not an acronym. The EQ-5D-5L consists of 2 pages: the EQ-5D descriptive system and the EQ 'visual analogue scale' (EQ VAS).

The descriptive system is made up of 5 sections: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.

The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative (numerical) measure of health outcome that reflect the patient's own judgement. A high score on the VAS means a better outcome. A low score on the VAS means a worse outcome.

Patient symptoms assessed on a scale of 0-100 monthlyFrom date of baseline, until end of trial follow-up at fourteen months post-baseline visit

This questionnaire will be sent to participants on a monthly basis for the duration of the study

SF-36 (Short Form 36 Health Survey Questionnaire) Individual Component ScoresFrom date of baseline, until end of trial follow-up at fourteen months post baseline visit

Trial Locations

Locations (12)

Royal Papworth Hospital

🇬🇧

Cambridge, United Kingdom

St. Richard's Hospital - University Hospitals Sussex

🇬🇧

Chichester, United Kingdom

University Hospitals Coventry and Warwickshire NHS Trust,

🇬🇧

Coventry, United Kingdom

Croydon University Hospital - Croydon Health Services

🇬🇧

Croydon, United Kingdom

Glenfield Hospital

🇬🇧

Leicester, United Kingdom

King's College Hospital

🇬🇧

London, United Kingdom

St Bartholomew's Hospital - Barts Health NHS Trust

🇬🇧

London, United Kingdom

Oxford University Hospitals

🇬🇧

Oxford, United Kingdom

University Hospitals Southampton

🇬🇧

Southampton, United Kingdom

Great Western Hospitals

🇬🇧

Swindon, United Kingdom

Worthing Hospital - University Hospitals Sussex

🇬🇧

Worthing, United Kingdom

Hammersmith Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath